Kim Samuel K, Manzerova Julia, Christos Paul, Wernicke A Gabriella, Parashar Bhupesh
Department of Radiation Oncology, Stitch Radiation Center, Weill Cornell Medical Center, New York, NY, 10065, USA.
Department of Biostatistics and Epidemiology, Weill Cornell Medical Center, New York, NY, 10065, USA.
Lung. 2017 Jun;195(3):341-346. doi: 10.1007/s00408-017-9992-6. Epub 2017 Mar 28.
To elucidate the role of radiation therapy (RT) in the treatment of surgically resected limited-stage small cell lung carcinoma (LSCLC).
We queried the SEER database from 1998 to 2012 to identify patients who were diagnosed with LSCLC as their only primary tumor. Kaplan-Meier analysis was utilized to determine disease-specific survival (DSS) and overall survival (OS), while multivariate analysis was used to compare survival in terms of patients and treatment characteristics.
Eight hundred twenty-three LSCLC patients were identified for inclusion within the study. 12-month DSS for patients who did not receive surgery or RT was 31.9% (95% CI 27.7-36.3), 93.3% (95% CI 71.6-90.5) for surgery alone, and 81.0% (95% CI 69.3-88.6) for surgery + RT. 12-month OS was 27.2% (95% CI 23.4-31.1), 74.7% (95% CI 62.6-83.4), and 78.3% (95% CI 66.4-86.4) for no surgery or RT, for surgery alone, and for surgery + RT, respectively. In terms of multivariate analysis, patients receiving surgery alone and patients receiving surgery + RT had a better DSS and OS than those who received neither treatment. However, OS (HR 1.60; 95% CI 0.93-2.75, p = 0.09) and DSS (HR 1.34; 95% CI 0.72-2.51, p = 0.37) were not significantly associated with patients receiving surgery alone compared to surgery + RT.
Surgery alone and surgery + RT were positively associated with DSS and OS compared to patients who did not receive surgery or RT. However, the addition of RT to surgery did not significantly predict DSS or OS compared to surgery alone.
阐明放射治疗(RT)在手术切除的局限期小细胞肺癌(LSCLC)治疗中的作用。
我们查询了1998年至2012年的监测、流行病学与最终结果(SEER)数据库,以确定被诊断为LSCLC且为唯一原发性肿瘤的患者。采用Kaplan-Meier分析来确定疾病特异性生存(DSS)和总生存(OS),同时使用多因素分析根据患者和治疗特征比较生存情况。
共确定823例LSCLC患者纳入本研究。未接受手术或放疗患者的12个月DSS为31.9%(95%置信区间27.7 - 36.3),单纯手术患者为93.3%(95%置信区间71.6 - 90.5),手术 + 放疗患者为81.0%(95%置信区间69.3 - 88.6)。未接受手术或放疗、单纯手术、手术 + 放疗患者的12个月OS分别为27.2%(95%置信区间23.4 - 31.1)、74.7%(95%置信区间62.6 - 83.4)和78.3%(95%置信区间66.4 - 86.4)。在多因素分析方面,单纯接受手术和接受手术 + 放疗的患者比未接受任何治疗的患者具有更好的DSS和OS。然而,与手术 + 放疗相比,单纯手术患者的OS(风险比[HR] 1.60;95%置信区间0.93 - 2.75,p = 0.09)和DSS(HR 1.34;95%置信区间0.72 - 2.51,p = 0.37)与手术 + 放疗无显著相关性。
与未接受手术或放疗的患者相比,单纯手术和手术 + 放疗与DSS和OS呈正相关。然而,与单纯手术相比,手术加放疗并不能显著预测DSS或OS。